In this retrospective study, we aimed to evaluate the utility of plasma ctDNA in patients with HER2-negative GC who lacked an effective therapeutic target to determine the mutational profile, assess tumor burden, and identify responders who were likely to benefit from ICI-containing treatments in accordance with ctDNA-based biomarkers. The gene discussed is ERBB2; the disease is neoplasm.